DNA methyltransferase(DNMT) inhibitors, 5-azacytidine (azacitidine; AZA) and 5-aza-2′-deoxycytidine (decitabine; DAC) have recently been used as chemotherapeutic agents for MDS patients who are not eligible for HSCT4, 5, 6, 7, 8, 9. Here, DNMT1 is linked to myelodysplastic syndrome.